Developing a Cell Therapy for Parkinson’s Disease
AMSBIO reports upon a publication that cites how its STEM-CELLBANKER® animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinson’s Disease that will soon be going into clinical trials.
Image credit: AMS Bio
Parkinson’s disease is one of the most common neurodegenerative diseases worldwide. Its main features include motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability, though non-motor symptoms are often also present. Currently the main therapy for Parkinson s disease consists of augmentation of dopamine levels in the brain via dopamine supplements or agonists or by inhibiting dopamine degradation. Treatment using this methodology is symptomatic but not long-lasting, and unfortunately has no neuroprotective effect. Cell therapy with grafts of human fetal tissue from the ventral mesencephalon have been carried out successfully, with multiple repo
Scientists, research organizations, and scientific journals have long relied upon the ISSCR Guidelines as the international standard for scientific and ethical rigor, oversight, and transparency in stem cell research.
Share this article
Share this article
COPENHAGEN, Denmark, May 25, 2021 /PRNewswire/ IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today the appointment of Muhammad Al-Hajj, PhD as Chief Scientific Officer. He will report to the CEO and be based in the Washington DC metro area, United States, where the company will establish an R&D site.
Dr. Muhammad Al-Hajj We are thrilled that Dr. Al-Hajj is joining IO Biotech at such an exciting time in the development of our company, said Mai-Britt Zocca, PhD, Chief Executive Officer, and founder of IO Biotech. He is a well-respected scientific leader with deep expertise and a proven track record in the field of immuno-oncology with expertise in translational medicine and biomarker discovery. Dr. Al-Hajj will play a pivotal role in harnessing the power of our T-win technology platform to build on our lead progr
Danish spin-out PanCryos has reached a licensing agreement with Takara Bio Europe AB (TBEAB) surrounding its clinical-grade human embryonic stem (hES) cell lines. Click to read more.
Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore's first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore.